xMedica

NCT01574053ClinicalTrials.gov

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into…

رصديةمطلوب 35,000 مشارك183 موقعاً20 دولة

الفئات

طب الأعصاب45%الأمراض النادرة والوراثية45%الطب النفسي والصحة النفسية10%

لم يُؤكَّد هذا السجل مؤخراً

أكّدت الجهة الراعية حالة هذا السجل آخر مرة في فبراير 2024. قد لا يكون دقيقاً بعد الآن.

لا يزال السجل يُظهر قيد التجنيد، لكن لم يؤكّد ذلك أحد منذ سنتين. تواصل مع موقع الدراسة قبل وضع أي خطط.

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2012-04-10; recorded start 2012-07-01
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Whether there is a comparison group is not stated in the registry recordThe record does not describe the study arms
  • Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 3 other studies in this databaseCounted from the lead sponsor named in the record (CHDI Foundation, Inc.)
  • No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: other.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 183 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEGA

A very large study, international in scope: 35,000 participants (target), run at 183 sites, across 20 countries.

How this score is built
  • Enrolment40/40

    35,000 participants (target)

  • Site count25/25

    183 sites

  • Country count15/15

    20 countries

  • Planned duration10/10

    Planned over about 603 months

  • Sponsor scale2/10

    CHDI Foundation, Inc. has led 4 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.

The primary objective of Enroll-HD is to develop a comprehensive repository of prospective and systematically collected clinical research data (demography, clinical features, family history, genetic characteristics) and biological specimens (blood) from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g., spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation). Enroll-HD is conceived as a broad-based and long-term project to maximize the efficiencies of non-clinical research and participation in clinical research. With more than 150 active clinical sites in 23 countries, Enroll-HD is now the largest HD database available and is accessible to any interested researcher - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.

الحالات

  • Huntington's Disease

الأهلية

الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءنعم
طريقة أخذ العيناتNON_PROBABILITY_SAMPLE

مجتمع الدراسة

Patients with HD and their family members are recruited from specialty clinics (Human Genetics, Neurology, Psychiatry) that advise and treat people affected by HD. In addition, in some areas community clinics and neurologists who see HD patients recruit participants for this study. Participants also receive information about the study through websites, clinical practices, support groups, advocacy newsletters, etc. and place a direct request to be considered for participation in the study. Community controls are identified by study site staff (using advertisements, flyers and newsletters) with the support of the Enroll-HD operational staff.

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Carriers: This group comprises the primary study population and consists of individuals who carry the HD gene expansion mutation. * Controls: This group comprises the comparator study population and consists of individuals who do not carry the HD expansion mutation. These two major categories can be further subdivided into six different subgroups of eligible individuals: * Manifest/Motor-manifest HD: Carriers with clinical features that are regarded in the opinion of the investigator as diagnostic of HD. * Pre-Manifest/-Motor-manifest HD: Carriers without clinical features regarded as diagnostic of HD. * Genotype Unknown: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has not undergone predictive testing for HD and therefore has an undetermined carrier status. * Genotype Negative: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has undergone predictive testing for HD and is known not to carry the HD expansion mutation. * Family Control: Family members or individuals not related by blood to carriers (e.g., spouses, partners, caregivers). * Community Controls: Individuals unrelated to HD carriers who did not grow up in a family affected by HD. Data collected from community controls will be used for generation of normative data for sub-studies. Participant status will be captured in the study database using 2 variables: 1) Investigator Determined Status: this will be based on clinical signs and symptoms and genotyping performed as part of medical care, and will be updated at every visit; and 2) Research Genotyping Status: this will be based on genotyping conducted as part of Enroll-HD study procedures. Based on research genotyping, participants will be reclassified under this variable from Genotype Unknown to 'Carriers' or 'Controls'. Investigators and participants will be blinded to this reclassification. Exclusion Criteria: * Individuals who do not meet inclusion criteria, * Individuals with choreic movement disorders in the context of a negative test for the HD gene mutation. * For Community Controls: those individuals with a major central nervous system disorder will be excluded (e.g. stroke, Parkinson's disease, multiple sclerosis, etc.). Participants under 18 may be eligible to participate (if they have juvenile-onset HD).

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

نوع الدراسةرصدية
المرحلةغير مذكور في سجل السجل
التخصيصغير مذكور في سجل السجل
نموذج التدخّلغير مذكور في سجل السجل
الغرض الأساسيغير مذكور في سجل السجل
التعميةغير مذكور في سجل السجل
التجنيدمطلوب 35,000 مشارك

الجهة الراعية والمتعاونون

  • CHDI Foundation, Inc. الجهة الراعية

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Motor Assessments: Unified Huntington's Disease Rating Scale (UHDRS) 99 Motor, UHDRS '99 Diagnostic Confidence Level

    The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. UHDRS 99 Motor, UHDRS Diagnostic Confidence Level.

    الإطار الزمني through study completion, an average of 1 year

  2. مقياس النتيجة الأولي

    Functional Assessments: UHDRS '99 Total Functional Capacity, UHDRS '99 Functional Assessment Scale, UHDRS '99 Independence Scale

    The Total Functional Capacity, Functional Assessment and Independence Subscales of the UHDRS '99 will be used to assess participants' functional status. The Total Functional Capacity scale has established psychometric properties including inter-rater reliability and validity, based on radiographic measures of disease progression.

    الإطار الزمني through study completion, an average of 1 year

  3. مقياس النتيجة الأولي

    Problem Behaviors Assessment-Short (PBA-s)

    The Problem Behavioral Assessment Short Version (PBA-s) will be used to perform behavioral assessments. This instrument measures frequency and severity of symptoms related to altered affect, thought content and coping styles.

    الإطار الزمني through study completion, an average of 1 year

  4. مقياس النتيجة الأولي

    Cognitive Assessments: Symbol Digit Modality Test; Stroop Color Naming; Stroop Word Reading; Categorical Verbal Fluency

    Cognition will be assessed using the Categorical Verbal Fluency Test, Symbol Digit Modality Test and Stroop Color and Word Reading Test. Verbal fluency is a commonly used neuropsychological test which examines the ability to spontaneously produce words orally within a fixed time span. For category fluency, words must be produced according to semantic constraints. The measure of performance used will be the number of correctly generated words within 60 seconds.

    الإطار الزمني through study completion, an average of 1 year

التواريخ

تاريخ البدء1 يوليو 2012 (فعلي)
الإتمام الأولي1 يناير 2062 (تقديري)
الإتمام1 يناير 2062 (تقديري)
أول نشر10 أبريل 2012 (تقديري)
آخر تحديث28 فبراير 2024
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةفبراير 2024

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

160 موقعاً قيد التجنيد

Argentina

المنشأةالمدينةالولاية أو المنطقةالحالة
Instituto de Neurociencias Buenos Aires (INEBA)Buenos Airesقيد التجنيد

Australia

المنشأةالمدينةالولاية أو المنطقةالحالة
Monash UniversityMelbourneVictoriaقيد التجنيد
University of Melbourne, Royal Melbourne HospitalParkvilleقيد التجنيد
The Neurosciences Unit - North Metropolitan HospitalPerthWestern Australiaقيد التجنيد
Westmead HospitalWestmeadNew South Walesقيد التجنيد

Austria

المنشأةالمدينةالولاية أو المنطقةالحالة
Universitatsklinik InnsbruckInnsbruckقيد التجنيد

Belgium

المنشأةالمدينةالولاية أو المنطقةالحالة
Bruxelles - ErasmeBrusselsقيد التجنيد
Institut de Pathologie et de Génétique (IPG)Charleroiقيد التجنيد
University Hospitals LeuvenLeuvenVlaams-Brabantقيد التجنيد
Hôpital du Beau Vallon ASBLSaint-Servaisقيد التجنيد

Canada

المنشأةالمدينةالولاية أو المنطقةالحالة
University of Calgary, Movement Disorders ProgramCalgaryAlbertaقيد التجنيد
University of Alberta (Glenrose)EdmontonAlbertaأُنهي
University of Alberta Hospital in EdmontonEdmontonAlbertaقيد التجنيد
Nova Scotia Health AuthorityHalifaxNova Scotiaقيد التجنيد
Centre for Movement DisordersMarkhamOntarioأُنهي
CHUM Hospital of Notre DameMontrealQuebecقيد التجنيد
The Ottawa HospitalOttawaOntarioقيد التجنيد
North York General HospitalTorontoOntarioقيد التجنيد
University of British ColumbiaVancouverBritish Columbiaقيد التجنيد

Chile

المنشأةالمدينةالولاية أو المنطقةالحالة
CETRAMSantiagoقيد التجنيد

Colombia

المنشأةالمدينةالولاية أو المنطقةالحالة
Servicios Médicos MS, Clínica de MarlyBogotáCundinamarcaقيد التجنيد
Universidad de Antioquia, Grupo de NeurocienciasMedellínAntioquiaقيد التجنيد

Denmark

المنشأةالمدينةالولاية أو المنطقةالحالة
University Hospital of AarhusAarhusقيد التجنيد
University Hospital of CopenhagenCopenhagenقيد التجنيد
University Hospital of OdenseOdenseقيد التجنيد

France

المنشأةالمدينةالولاية أو المنطقةالحالة
CHU Amiens-PicardieAmiensقيد التجنيد
CHU Angers, Centre de Référence Maladies NeurogénétiquesAngersقيد التجنيد
Bordeaux - Huntington Disease competencies centerBordeauxقيد التجنيد
CHU Gabriel-MontpiedClermont-Ferrandقيد التجنيد
Hôpital Henri Mondor, Centre d'Investigation CliniqueCréteilقيد التجنيد
Lille-Amiens - Huntington Disease Constituent siteLilleقيد التجنيد
Hôpital La TimoneMarseilleقيد التجنيد
CHU MontpellierMontpellierقيد التجنيد
Institut du Cerveau et de la Moelle EpinièreParisقيد التجنيد
Hôpitaux Universitaires de Strasbourg Hôpital de Hautepierre-Service de NeurologieStrasbourgAlsace Lorraineقيد التجنيد
Hôpital Purpan, Centre d'Investigation CliniqueToulouseقيد التجنيد

Germany

المنشأةالمدينةالولاية أو المنطقةالحالة
University Hospital AachenAachenقيد التجنيد
University of BerlinBerlinقيد التجنيد
St. Josef und St. Elisabeth HospitalBochumقيد التجنيد
University Hospital Carl Gustav Carus DresdenDresdenقيد التجنيد
University Hospital ErlangenErlangenقيد التجنيد
University Medical Center FreiburgFreiburg im Breisgauقيد التجنيد
Paracelsus Elena Klinik KasselKasselقيد التجنيد
University Hospital Schleswig-HolsteinLübeckقيد التجنيد
University Hospital Giessen and MarburgMarburgأُنهي
Technical University of MunichMunichقيد التجنيد
George-Huntington-Institut GmbHMünsterقيد التجنيد
kbo-Isar-Amper-Klinikum Taufkirchen (Vils)Taufkirchenقيد التجنيد
University Hopsital of UlmUlmقيد التجنيد
University Hospital of WuerzburgWürzburgقيد التجنيد

يُدرَج 133 موقعاً إضافياً في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.

يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.

السجل: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT01574053